FibroGen reports third PhIII failure in two months, this time in idiopathic pulmonary fibrosis

FibroGen’s pamrevlumab failed another Phase III study — the biotech’s third late-stage miss in two months — and its shares plummeted 76% before Monday’s opening bell.

The company said Monday that its antibody pamrevlumab was not better than placebo at a lung function test examining the amount of air people…
Click here to view original post